27 November 2018 - - US-based biopharmaceutical company Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) plans to offer and sell, in an underwritten public offering and subject to market and other conditions, USD 200m of its common stock, the company said.

There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

BofA Merrill Lynch, J.P. Morgan Securities LLC and Goldman Sachs and Co. LLC are acting as the joint book-running managers for the offering.

Acadia plans to grant the underwriters a 30-day option to purchase up to an additional USD 30m of its common stock.

The shares of common stock described above are being offered by ACADIA pursuant to a shelf registration statement filed by Acadia with the Securities and Exchange Commission that became automatically effective on November 26, 2018.

Acadia is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders.

Acadia has developed and is commercialising the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis.

In addition, Acadia has ongoing clinical development efforts in additional areas with significant unmet need, including dementia-related psychosis, schizophrenia inadequate response, schizophrenia-negative symptoms, major depressive disorder, and Rett syndrome.